24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of secukinumab in the NHS in England for the treatment of patients with non-radiographic axial spondyloarthritis.

Secukinumab is recommended as an option for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI, or both) that has responded inadequately to non-steroidal anti-inflammatory drugs. 

Secukinumab is recommended only if:

• the disease has responded inadequately to tumour necrosis factor alfa inhibitors, or these are contraindicated or not suitable
• Novartis provides secukinumab according to the commercial arrangement

Read NICE appraisal consultation document for secukinumab